This resolution expresses the House of Representatives' strong support for implementing most-favored-nation drug pricing for patients in the United States. It highlights that US drug prices are significantly higher than in other developed countries, leading to substantial financial burdens and access issues for American citizens. The resolution notes bipartisan support for lowering drug costs and references recent executive actions aimed at aligning US drug prices with international benchmarks. The resolution specifically affirms that US patients should not be charged more than those in other countries for identical prescription drugs. It commits to reducing drug costs by supporting policies that align US drug pricing with other developed nations, expanding Medicare drug price negotiation , and fostering greater price competition within the pharmaceutical market to ensure access to high-quality, affordable prescription drugs for all US citizens.